Previous 10 | Next 10 |
LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, and Noile-Immune Biotech, Inc., Tokyo, Japan, a biotechnology company focusing on the development of innovati...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) had a rocky time last week, starting at 3,467.3 points and reaching a low of 3,396.02 points on Thursday (November 7). By Friday (November 8), the index had recovered slightly to reach 3,454.53 points as of 1:59 p.m. EST. On Tuesday (...
Autolus Therapeutics plc (AUTL) Q3 2019 Earnings Conference Call November 07, 2019 8:30 AM ET Company Participants Silvia Taylor - Vice President Global Corporate Affairs & Communications Christian Itin - Chairman & Chief Executive Officer Andrew Oakley - Chief Financial ...
LONDON, Nov. 09, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today presented pre-clinical data on AUTO6NG, the company’s next gene...
Image source: The Motley Fool. Autolus Therapeutics Plc (NASDAQ: AUTL) Q3 2019 Earnings Call Nov 07, 2019 , 8:30 a.m. ET Operator Continue reading
Autolus Therapeutics (NASDAQ: AUTL ): Q3 GAAP EPS of -$0.61 beats by $0.25 . More news on: Autolus Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more ...
LONDON, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the third quarter ended September 30, 2019. ...
LONDON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced four oral and two poster presentations related to its AUTO1, AUTO2...
Autolus Therapeutics (NASDAQ: AUTL ) got a boost from the US Food and Drug Administration (FDA) after the agency gave orphan drug designation to the company’s AUTO1 treatment for acute lymphoblastic leukemia (ALL). In a press release on Tuesday (November 5), the company sa...
LONDON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced today pre-clinical data on AUTO6NG, the company’s next gene...
News, Short Squeeze, Breakout and More Instantly...
Autolus Therapeutics plc Company Name:
AUTL Stock Symbol:
NASDAQ Market:
Autolus Therapeutics plc Website:
LONDON, July 26, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2024 financial results and operational highlights befo...
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention Ongoing CAR T persistence was associated wi...